• To evaluate the biologic heterogeneity of prostatic conditions (both benign and malignant) [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  

• To evaluate changes in these parameters in patients treated with: Chemotherapy, Hormonal therapy, Radiation therapy, Biologic approaches, or Other targeted therapies, alone or in combination, with respect to clinical outcomes. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  
• Invest host immune resp to ca by assess whether pts have cytotoxic (CD8+) or helper (CD4+) T lymp or antibodies in immune repertoire that can react w specific antigens, or if lymphocytes can be modified ex vivo to gener prost cancer spec immune resp. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  
• To utilize prostatic cancer tissue obtained at the time of a biopsy or surgical procedure, phlebotomy or leukopheresis in short-term culture and in immunocompromised animals to develop immortalized prostate cancer xenografts and cell lines. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  
• To evaluate protein and peptide expression patterns of sera and urine specimens of patients with prostate cancer. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  

The therapeutics program for advanced prostate cancer is based on the hypothesis that the factors contributing to and associated with progression change as the disease evolves. To categorize these changes we now consider the disease as a series of states. The states represent points where an intervention might be considered to prevent cancer from developing, to eliminate established disease, or to delay progression. The states also represent clinically significant milestones that can be used to assess treatment effects. The present study is designed to characterize benign and malignant prostatic conditions representing the time before a cancer diagnosis is established to death from disease, to evaluate the host immune response to tumors, to identify determinants that can be used to define prognosis or for therapeutic attack, and to develop human tumor derived models for laboratory studies. The study involves the acquisition of tumor, bone marrow, blood, and urine from men with benign and malignant prostatic conditions representing the clinical spectrum of the illness. It seeks to define more precisely the interplay between clinical and biologic factors contributing to the development and progression of the disease in the individual so that treatment selection can be refined, treatment effects can be monitored, and more effective regimens designed.